Pulmonary hypertension
(PAH)

PAH is a serious and progressive disease with various causes and no cure. [1], [2]

There are five groups of PAH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1]

Our focus has been on a specific, rare form of PAH (WHO Group 1) called pulmonary arterial hypertension (PAH).[1]

We are spearheading a new era for PAH, working to transform the disease into a long-term manageable condition, so that patients can live a full life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

PAH (WHO Group 1) is a rare, progressive and relentless disease, where the pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart. [1]

Despite recent advances, PAH remains a severely debilitating condition that leads to heart disease and early death. Early diagnosis and treatment are critical to helping improve life expectancy but PAH is difficult to diagnose and there is currently no cure.[2]